

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application No. 10/526,697

Confirmation No. 9619

Applicant: Dudley et al.

Filed: May 5, 2005

TC/AU: 1644

Examiner: Michail A. Belyavskyi

Docket No.: 233876 (Client Reference No. E-275-2002/1-US-02)

Customer No.: 45733

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

DECLARATION UNDER 37 C.F.R. § 1.131 OF MARK E. DUDLEY


I, Mark E. Dudley, do hereby declare as follows:

1. I am a co-inventor of pending claims in the above-referenced patent application, along with Steven Rosenberg and John Wunderlich.
2. We conceived of and reduced to practice the claimed invention in the United States before July 2, 2001, as evidenced by the following:
  - a. attached to this Declaration is a true and accurate copy of a report prepared by myself. The report summarizes research performed involving the administration of <sup>non-</sup>myeloablative lymphodepleting chemotherapy followed by adoptive transfer of autologous T cells to melanoma patients.
3. The treatment dates of Patients A-F which have been deleted from the report are prior to July 2, 2001.
4. I hereby declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true,

In re Appln. of Dudley et al.  
Application No. 10/526,697

that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 11-14-2007

  
Mark E. Dudley, Ph.D.

ID Ref	Lvl	Patient	Testament Characteristics			Current clinical			Patient Characteristics			Vax	AL	Other	DOD	notes
			HRM	Date	Cells	AGE	Rel (ind)	Neat (du)	Age (Stm)	HLA	Sequences (mets)					
	A	Patient			33.0	A	PR (29)		1804	A02:A31	AX MT PV	2	IV			
	B	Patient			33.0	G-A	PR (8)		107	A01:A02	SK SU	3	IV	w/ clone		
	C	Patient			39.8	G-A	NR		437	A02:A31	SK SU	3	IV	w/ clones		
	D	Patient			34.0	G-M	PR (2)		571	A02:A29	SK	3	IV	w/ clone		
	E	Patient			30.0	G-A	NR-M		1504	A02:A03	NR BN IL LU	3	IV	w/ clone		
	F	Patient			36.5	A	PR (28)		371	A02:A11	NR SU IP LU		IV			
	G	Patient			122.6	NLA	NR		4404	A02:A03	CE CL SU	3	IV			
	H	Patient			24.5	G	NR		4804	A02:A30	SU		IV			
	I	Patient			93.7	NLA	PR (12)		5714	A02:A03	SK SU		IV			
	J	Patient			109.0	M	PR (14)		5574	A02:A0205	BN SK SU		IV			
	K	Patient			130.0	M	NR		3874	A02:A11	BN SU CY LI PA		IV			
	L	Patient			137.0	M	NR-M		371	A02:A11	BN IL SU GB LI LU		IV			
	M	Patient			77.0	NE	NR		411	A02	SU		IV		up clone CR	